Using point-of-care real-world data to analyze patterns, Amplity, a contract sales and medical outsourcing partner, found that biomarker testing for patients with non-small cell lung cancer (NSCLC) in the United States is significantly underutilized. Presented on June 3 at the 2024 ASCO Annual Meeting in Chicago, “Biomarker Testing and Targeted Therapy Use Among Patients With Non-Small Cell Lung Cancer in the United States: An Analysis Using a Physician Notes Real-World Database,” highlights critical gaps in testing practices and underscores the need for improved diagnostic strategies.
By using natural language processing to examine more than 70 million records, this study showed that:
“Our data further suggest that even when biomarker testing is conducted, and actionable mutations are confirmed, many patients may not be receiving an appropriate targeted therapy,” says Melanie Jardim, PhD, an Amplity executive and principal investigator on the study.
“When working with healthcare providers and clients, Amplity’s goal is to help remove barriers and address social determinants related to biomarker testing and treatment, ultimately enhancing outcomes across all populations,” adds Chris Baker, CEO of Amplity.
Disrupting Data Norms
AnswerY, our proprietary HIPAA-compliant database + platform, cuts through marketplace noise with data sourced from unfiltered patient-provider conversations. Powered by NLP + AI, AnswerY explains the “why” behind treatment rationale for improved care + smarter strategies. Exclusive intel, straight from the source.
Pharma at its best: Quicker. Better. Nicer
We are your full-service go-to partners delivering both flexible and specialized medical and commercial services. No matter where you are in the lifecycle of your drug, we scale with ease to maximize resources and improve impact. Our people-driven, tech enabled DNA fuels everything we do.
To learn more about AnswerY, please reach out to Vikram Singh, Vice President, Client Partnerships, [email protected].
To connect with Amplity’s Marketing and PR team, please email [email protected].
